SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. - SNSS
NEW YORK, May 2, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sunesis Pharmaceuticals, Inc. ("Sunesis" or the "Company") (NASDAQ: SNSS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
The investigation concerns whether Sunesis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On May 2, 2017, Sunesis announced that the Company will withdraw its European Marketing Authorization Application for vosaroxin, the Company's proposed treatment for relapsed/refractory AML. Sunesis advised investors that the decision followed recent interactions with the European Medicine Agency's Committee for Medicinal Products for Human Use, during which the Company learned that the committee was likely to formally adopt a negative opinion in its evaluation of the product.
On this news, Sunesis's share price has fallen as much as $0.81, or 22.13%, during intraday trading on May 2, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
SOURCE Pomerantz LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article